$2.650
+0.020 (+0.76%)At close
RPTX News
RPTX Events
Repare Therapeutics Shareholders Approve Acquisition
Repare Therapeutics announced that its shareholders have approved the acquisition of all of the issued and outstanding common shares of the company by XenoTherapeutics and Xeno Acquisition Corp. by way of a statutory plan of arrangement at the special meeting of Shareholders held on January 16. The arrangement is subject to the approval of the Superior Court of Quebec and other customary closing conditions. The Court hearing for the final order to approve the Arrangement is expected to take place on January 23, and, assuming receipt of the approval of the Court and satisfaction of other customary conditions to closing, the completion of the arrangement is expected to occur on or about January 28.
Repare Therapeutics Enters $30 Million Asset Purchase Agreement with Gilead Sciences
Repare Therapeutics (RPTX) announced a definitive asset purchase agreement for Gilead Sciences (GILD) to acquire Repare's polymerase theta ATPase inhibitor, RP-3467. Under the terms of the Gilead Agreement, Repare will receive up to $30 million in total consideration, including a $25 million upfront payment, subject to customary holdbacks and adjustments, and an additional $5 million payment upon completion of specified technology transfer activities. On November 14, 2025, Repare announced that it had entered into a definitive arrangement agreement with XenoTherapeutics and Xeno Acquisition, pursuant to which Xeno will acquire all of the issued and outstanding common shares of Repare. Under the terms of the Arrangement Agreement, Repare shareholders will receive a cash payment per Common Share that will be determined based upon Repare's cash balance at closing of the Arrangement Transaction. The upfront portion of the consideration payable under the Gilead Agreement has increased Repare's cash balance and, therefore, has also increased the estimated Closing Net Cash Amount. Based on Repare's revised estimate of the Closing Net Cash Amount, it is now currently estimated that each Repare shareholder will receive a cash payment of approximately US$2.20 per Common Share at the Arrangement Closing.
Repare Therapeutics announces Q3 earnings per share of 8 cents compared to a loss of 81 cents in the previous year.
Q3 revenue from collaboration agreements were $11.6M and $11.9M for the three and nine months ended September 30, 2025, respectively, as compared to nil and $53.5M for three and nine months ended September 30, 2024.
XenoTherapeutics to Purchase Repare Therapeutics for $1.82 per Share Along with One Contingent Value Right
Repare Therapeutics announced that it has entered into a definitive arrangement agreement with XenoTherapeutics and Xeno Acquisition Corp., a non-profit biotechnology company, pursuant to which Xeno will acquire all of the issued and outstanding common shares of Repare. Under the terms of the Arrangement Agreement, Repare shareholders will receive a cash payment per Common Share that will be determined based upon Repare's cash balance at closing of the Transaction after deducting certain transaction costs and the aggregate amount of outstanding liabilities. Based on Repare's current estimates of the Closing Net Cash Amount and the expected timing for Closing, it is currently estimated that each Repare shareholder will receive a cash payment of $1.82 per Common Share at Closing. In addition, each Repare shareholder will also receive one non-transferable contingent value right for each Common Share that entitles the holder to receive certain cash payments, including: 100% of certain additional receivables that may be received by Repare within ninety days following the Closing; A percentage of the net proceeds received from Repare's existing partnerships with Bristol-Myers Squibb, Debiopharm and DCx Biotherapeutics, as follows: (i) 90% received from the Closing date until the 2nd anniversary thereof, (ii) 85% received from the 2nd anniversary of the Closing date until the 4th anniversary of the Closing date, (iii) 80% received from the 4th anniversary of the Closing date until the 6th anniversary of the Closing date, and (iv) 75% received from the 6th anniversary of the Closing date until the 10th anniversary of the Closing date; 100% of the net proceeds received by the 10th anniversary of the Closing date for any license or disposition of Repare's product candidates and/or intellectual property related to Repare's RP-1664 program, RP-3500 (Camonsertib) program, or any other license or disposition of Repare's product candidates or research programs if such license or disposition is entered into prior to the Closing date; 100% of the net proceeds received by the 10th anniversary of the Closing date for any license or disposition of Repare's Pol program, RP-3467, to any person with whom negotiations were initiated prior to the Closing date; and 50% of the net proceeds received by the 10th anniversary of the Closing date for any license or disposition of Repare's product candidates and/or intellectual property that occurs within 10 years following the Closing date if such license or disposition is entered into following the Closing date. The Transaction is expected to close in the first quarter of 2026.
Repare Therapeutics reports Q2 EPS (39c) vs. (82c) last year
Reports Q2 revenue $250,000, consensus $1.67M. "We remain focused on exploring strategic alternatives and partnerships across our portfolio to enhance long-term shareholder value, as exemplified by our recent worldwide licensing agreement with Debiopharm for lunresertib and out-licensing of early-stage discovery platforms to DCx," said Steve Forte, President, Chief Executive Officer and Chief Financial Officer of Repare. "In parallel to evaluating these strategic opportunities for our remaining programs, we expect to deliver initial data from the LIONS and POLAR trials in the fourth quarter."
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.